Paul Booth is a partner at Edell, Shapiro and Finnan and has been practicing patent law for over 23 years. He counsels clients in the areas of biotechnology, pharmaceuticals, diagnostics and industrial chemistry, and has a broad range of experience including the strategic development of international patent portfolios, preparation of validity and infringement opinions, due diligence investigations, and district court and appellate litigation. He has particular skill in patent issues in the pharmaceutical and biotechnology fields, including small molecule drugs, protein drugs, recombinant cell therapy, with particularly extensive experience in antibody technology.
Prior to his legal career Paul was a scientist in the biotechnology industry and directed research groups in the fields of catalytic antibodies, cell adhesion, lymphokines, and cytokines. He was a research fellow at Harvard Medical School and a postdoctoral researcher at Cambridge University and also has extensive research training in synthetic organic chemistry, including the development of new methodologies for the synthesis of macrolide and glycopeptide antibiotics.